BioInvent International AB (STU:BIX)
€ 3.75 -0.025 (-0.66%) Market Cap: 248.71 Mil Enterprise Value: 157.51 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 47/100

Q4 2023 BioInvent International AB Earnings Call Transcript

Feb 22, 2024 / 01:00PM GMT
Release Date Price: €1.39 (+0.29%)
Operator

Welcome to the BioInvent Q4 Report 2023 Conference Call. (Operator Instructions) Now I will hand the conference over to the speakers: CEO Martin Welschof, CFO Stefan Ericsson. Please go ahead.

Martin Welschof
BioInvent International AB - CEO

Yes, welcome, everybody, to our year-end report. And we will guide you through a number of slides. First, I will give you a summary of what has happened with some focus areas. And then at the end, Stefan Ericsson, the CFO, will give you the financials. And I am the CEO, Martin Welschof.

So we'll start on slide number 3, where we have a summary of the main events in the fourth quarter. And I would like to start with our program, BI-1808, which is our lead program targeting TNF receptor 2. And we had very interesting, positive data from the clinical Phase 1/2a, which is currently ongoing, where we test the antibody, BI-1808, as a single agent. And we presented that at SITC. And I will come back to the data a little bit later. Then we also have shown preclinical data providing clear evidence of the potential of our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot